%PDF-1.4
%
22 0 obj
<>
endobj
19 0 obj
<>
endobj
68 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T19:53:17Z
2024-03-28T21:43:40-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T21:43:40-07:00
application/pdf
Heather
2002-672.sept
uuid:679191a7-1dd2-11b2-0a00-1a0a275dc400
uuid:679191a9-1dd2-11b2-0a00-810000000000
endstream
endobj
8 0 obj
<>
endobj
9 0 obj
<>
endobj
23 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
74 0 obj
[78 0 R]
endobj
75 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.1521 Tw 10 0 0 10 54 713.1616 Tm
[(facilities and can be used in multicenter trials. Moreover)39.8 (,)]TJ
0.0687 Tw 0 -1.2 TD
(because of the pain in patients with OA, image acquisition)Tj
0.05769 Tw T*
[(should preferably be completed quickly)64.9 (, but without losing)]TJ
-0.00011 Tc -0.0327 Tw T*
[(image quality)64.8 (. )17.9 (This is critical for analysis of disease progres-)]TJ
0 Tc 0.01311 Tw T*
(sion over time. MRI should hopefully reduce the number of)Tj
0.2115 Tw T*
(patients needed, improve retention of these patients, and)Tj
0.23869 Tw T*
(reduce the overall costs and the length of clinical trials)Tj
-0.00011 Tc 0.02499 Tw T*
(related to OA. )Tj
0.02 Tc 0.61391 Tw 1.2 -1.2 Td
(Another advantage, compared with conventional)Tj
0 Tc 0.0314 Tw -1.2 -1.2 Td
(imaging technologies, is the ability of MR images to assess)Tj
0.34241 Tw T*
(all the joint structure, including the cartilage, menisci,)Tj
0.1279 Tw T*
(synovial tissue, and ligaments. For example, MRI evalua-)Tj
0.09061 Tw T*
(tion of cartilage loss can visualize other structures such as)Tj
0.2751 Tw T*
(meniscal damage or misalignment. In this issue of )Tj
/TT1 1 Tf
-0.00011 Tc 0 Tw 22.5002 0 Td
(The)Tj
0 Tc -22.5002 -1.2 Td
(Journal)Tj
/TT0 1 Tf
6.5 0 0 6.5 85.106 548.4615 Tm
(12)Tj
/TT1 1 Tf
10 0 0 10 91.6059 545.1616 Tm
(, )Tj
/TT0 1 Tf
0.5864 0 Td
(Cicuttini, )Tj
/TT1 1 Tf
0.0864 Tw 4.0864 0 Td
(et al)Tj
/TT0 1 Tf
-0.00011 Tc 2.1723 0 Td
(suggest there was more cartilage)Tj
0 Tc 0.0567 Tw -10.6058 -1.2 Td
(loss over time in patients who underwent partial meniscec-)Tj
-0.00011 Tc 0.0965 Tw T*
[(tomy)64.8 (. )17.8 (Their results suggest the strong role of the meniscal)]TJ
0 Tc 0.21581 Tw T*
(apparatus in protecting cartilage, especially in elderly or)Tj
0.13 Tw T*
[(obese subjects, or those with joint instability)64.9 (. )17.8 (What is not)]TJ
0.18381 Tw T*
(known is whether this is a population at risk that would)Tj
0.0533 Tw T*
(benefit from the \223chondroprotective\224 agents or whether we)Tj
-0.036 Tw T*
(should avoid treating a disease course that may be relentless.)Tj
0.0731 Tw 1.2 -1.2 Td
(The implication of the MRI findings about the cartilage)Tj
0.11211 Tw -1.2 -1.2 Td
(and the surrounding tissues may also influence the defini-)Tj
0.08321 Tw T*
[(tion of \223primary\224 OA)-278.3 (in the future. )17.8 (The )54.9 (American College)]TJ
0.11079 Tw T*
[(of Rheumatology criteria of the primary OA)-305.9 (of the knee)]TJ
0 Tw 6.5 0 0 6.5 287.5002 416.4616 Tm
(13)Tj
0.1125 Tw 10 0 0 10 54 401.1616 Tm
(are actually based on clinical and/or radiological findings.)Tj
-0.0358 Tw T*
(Since the cartilage is not vascularized or innervated, the pain)Tj
-0.0054 Tw T*
[(experienced in OA)-189.7 (is likely to originate from bone, synovial)]TJ
0.1088 Tw T*
(capsule, or ligament damage. \223Pure\224 anatomical cartilage)Tj
0.00639 Tw T*
(loss over time, if considered to define primary OA, may not)Tj
0.1228 Tw T*
(be reflected by changes in symptoms, may precede radio-)Tj
0.2014 Tw T*
[(logical changes considerably)64.9 (, and may be accelerated by)]TJ
0.02499 Tw T*
(unsuspected concomitant meniscal damage.)Tj
0.33389 Tw 1.2 -1.2 Td
[(The future of OA)-529.1 (research pertaining to anatomical)]TJ
0.02879 Tw -1.2 -1.2 Td
(damage and its prevention or repair is similar to the experi-)Tj
0.0773 Tw T*
(ence in osteoporosis many years ago: significant bone loss)Tj
-0.00011 Tc 0.1284 Tw T*
(was necessary to \223see\224 osteoporosis on plain radiographs.)Tj
0 Tc -0.024 Tw T*
[(W)39.8 (ith the advent of osteodensitometry)64.9 (, very small changes of)]TJ
0.0213 Tw T*
[(bone mass could be detected. )17.8 (This outcome tool opened the)]TJ
-0.01559 Tw T*
(door to clinical research on new therapies to slow or prevent)Tj
0.0041 Tw T*
[(bone mass loss. )17.8 (W)79.8 (e know the ef)17.8 (fect of these medications on)]TJ
-0.0327 Tw T*
[(osteoporosis today)64.9 (. Similarly)65 (, quantification of cartilage loss)]TJ
0.0715 Tw T*
[(over time will improve the monitoring of OA)-266.6 (and possibly)]TJ
0.0148 Tw T*
(help us develop new interventions to prevent this extremely)Tj
0.02499 Tw T*
(prevalent disease.)Tj
/TT2 1 Tf
-0.0002 Tc 0 -2.4 TD
[(JEAN-PIERRE RA)91.6 (YNAULD,)]TJ
/TT0 1 Tf
-0.00011 Tc 6 0 0 6 185.4986 149.1616 Tm
(MD, FRCPC,)Tj
8 0 0 8 54 139.1616 Tm
(Head, Osteoarthritis Clinical Research Program, )Tj
0 Tc 0 -1.25 TD
(Montreal Rheumatology Institute and )Tj
-0.00011 Tc 0.825 -1.25 Td
(Centre Hospitalier de l\222Universit\351 de Montr\351al \227 H\364pital \
Notre-Dame, )Tj
0 Tc -0.825 -1.25 Td
[(Assistant Professor)39.8 (, Department of Medicine,)]TJ
T*
(University of Montr\351al, Montr\351al, Qu\351bec, Canada.)Tj
/TT1 1 Tf
-0.00011 Tc 0.23331 Tw 33 76.921 Td
[(Addr)36.8 (ess r)36.8 (eprint r)36.8 (equests to Dr)110.7 (. J-P)128.8 (. Raynauld, Osteoarthritis Resear)36.8 (ch)]TJ
0 Tc 0.02499 Tw T*
[(Unit, 1551 East Ontario St., Montr)36.9 (eal, Quebec, Canada H2L)-257.2 (1S6.)]TJ
/TT2 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 318 680.5293 Tm
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 325 670.5293 Tm
[(1.)-875 (Bellamy N, Buchanan )17.8 (WW)91.8 (, Goldsmith H, et al. )17.8 (V)111.1 (alidation study of)]TJ
1.675 -1.25 Td
[(the )17.8 (WOMAC. )54.9 (A)-219.8 (health status instrument for measuring clinically)]TJ
T*
(important patient relevant outcomes to antirheumatic drug therapy)Tj
T*
(in patients with osteoarthritis of the hip or knee. J Rheumatol)Tj
0 Tw T*
(1988;15:1833-40.)Tj
0.0249 Tw -1.675 -1.25 Td
[(2.)-875 (Altman RD, Fries JF)79.8 (, Bloch DA, et al. Radiographic assessment of)]TJ
1.675 -1.25 Td
[(progression in osteoarthritis. )54.8 (Arthritis Rheum 1987;30:1214-25.)]TJ
-1.675 -1.25 Td
[(3.)-875 (Buckland-W)39.8 (right JC. Quantitative radiography of osteoarthritis.)]TJ
1.675 -1.25 Td
(Ann Rheum Dis 1994;53:268-75.)Tj
-1.675 -1.25 Td
[(4.)-875 (Lequesne M, Glimet )17.7 (T)74 (,)0.1 ( Masse JP)110.8 (, Orvain J. Speed of the joint)]TJ
1.675 -1.25 Td
(narrowing in primary medical osteoarthritis of the knee over 3-5)Tj
T*
(years. Osteoarthritis Cartilage 1998;1:23.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Adams JG, McAlindon )17.7 (T)73.9 (, Dimasi M, Carey J, Eustace S.)]TJ
0 Tc 1.675 -1.25 Td
(Contribution of meniscal extrusion and cartilage loss to joint space)Tj
T*
(narrowing in osteoarthritis. Clin Radiol 1999;54:502-6. )Tj
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (A)91.9 (yral X, Gueguen )54.8 (A, Ike R)54.8 (W)91.7 (, et al. Inter)19.7 (-observer reliability of the)]TJ
0 Tc 1.675 -1.25 Td
(arthroscopic quantification of chondropathy of the knee.)Tj
T*
(Osteoarthritis Cartilage 1998;6:160-6.)Tj
-1.675 -1.25 Td
[(7.)-875 (Eckstein F)79.8 (, )17.7 (W)79.8 (esthof)17.8 (f J, Sittek H, et al. In vivo reproducibility of)]TJ
1.675 -1.25 Td
(three-dimensional cartilage volume and thickness measurements)Tj
T*
[(with MR imaging. )54.9 (AJR )54.9 (Am J Roentgenol 1998;170:593-7. )]TJ
-1.675 -1.25 Td
[(8.)-875 (Calvo E, Palacios I, Delgado E, et al. High-resolution MRI detects)]TJ
1.675 -1.25 Td
(cartilage swelling at the early stages of experimental osteoarthritis.)Tj
T*
(Osteoarthritis Cartilage 2001;9:463-72. )Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Bur)17.7 (gkart R, Glaser C, Hyhlik-Durr )54.8 (A, Englmeier KH, Reiser M,)]TJ
1.675 -1.25 Td
[(Eckstein F)79.7 (. Magnetic resonance imaging-based assessment of)]TJ
0 Tc T*
[(cartilage loss in severe osteoarthritis: accuracy)64.9 (, precision, and)]TJ
T*
[(diagnostic value. )54.9 (Arthritis Rheum 2001;44:2072-7.)]TJ
-2.175 -1.25 Td
[(10.)-875 (Peterfy CG, van Dijke CF)79.8 (, Janzen DL, et al. Quantification of)]TJ
2.175 -1.25 Td
(articular cartilage in the knee with pulsed saturation transfer)Tj
T*
(subtraction and fat-suppressed MR imaging: optimization and)Tj
T*
(validation. Radiology 1994;192:485-91. )Tj
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Raynauld JP)110.7 (, Pelletier JP)110.7 (, Beaudoin G, et al. )17.7 (T)69.7 (wo-year study in)]TJ
0 Tc 2.1381 -1.25 Td
(osteoarthritis patients: following the progression of the disease by)Tj
T*
(magnetic resonance imaging using a novel quantification imaging)Tj
-0.00011 Tc T*
[(system [abstract]. European Congress of Rheumatology)64.8 (, EULAR)]TJ
0 Tc T*
[(2002, Stockholm, Sweden, June 12-15, 2002: )54.8 (Abstract SA)110.8 (T0253.)]TJ
-2.175 -1.25 Td
[(12.)-875 (Cicuttini FM, Forbes )54.8 (A, )36.8 (Y)111.1 (uanyuan )17.7 (W)91.8 (, Rush G, Stuckey SL. Rate of)]TJ
2.175 -1.25 Td
[(knee cartilage loss after partial meniscectomy)64.9 (. J Rheumatol)]TJ
0 Tw T*
(2002;29:1954-6.)Tj
0.0249 Tw -2.175 -1.25 Td
[(13.)-875 (Altman RD, )54.8 (Asch E, Bloch DA, et al. Development of criteria for)]TJ
2.175 -1.25 Td
(the classification and reporting of osteoarthritis. Classification of)Tj
T*
[(osteoarthritis of the knee. )54.9 (Arthritis Rheum 1986;29:1039-49.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:9)Tj
0 Tw -46.2952 -0.0313 Td
(1810)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 58.75 407.5 -10.83 re
f*
0.5 w
102.25 58.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
63 0 obj
<>
endobj
73 0 obj
<>
endobj
26 0 obj
<>
endobj
27 0 obj
<>
endobj
4 0 obj
<>
endobj
5 0 obj
<>
endobj
6 0 obj
<>stream
HdV
pT}叠 ,1$>~̺h3$R%?4II"F% VVD^1*L+a@+0eZAS+PSo7;s{ι bQΨn5iK;_bmfoYIkᡯO }oK-ݧu6VҧAM>
+f̴{V7>JffClEczXN.5xK7@7.m_|dgQ|@16uNcJ}o5?7FZ |`$ޥ㰰
{#[(DD+j[C%4 H F^.>,RqLravR6Ի,xEvqD>BX8-&$QG?tZE=:a*Ƶ3n1Z!yJBxO\'BjzUa(J%ls؊7Ѕ(DG-SoO_xc#^[(9J.{[.v9y"CdrDqYVF FnC88O+BAtv#xd-^QMl4Be\a#Q,ƈ2QE.HC]viƋ33~N}eU5CaD09
.#ldğ٫{ %L-ŭb2yUeeGdRRc *Z-X%V~ 4c۹f=ъXu.v#_".D*#bl1]!n#A1i\1UFOEFi>T9KΑȍ1Ըhf|ʱZU3"P֩Mꔺ܈ј[9,e|ӄͬN뜣q'8Ϊ~}L3089nGKDfvs(։fV~`/,S$w?YD||P"g9!q1ʘki;njcfn2',Xj~k[)SSק>z])goJp { D\.;FȃɻG4;ƬuW[Yr(dXeF3|W=û5OF8,MQf- '9Յxohoy@p`7?oP9=/of4@a.z!QbO{;FF#x*VF]5ﵚAjH3^Y (FlvU*H?+NKOw
.ݗވ>uDqJEad32,2
;{EkD;qaWf#g權Hf2PIBvȹ y\Ruv}
&ƮY/QMW8FґQgv*БXm[)KfJbջZxiVVV82{"Z;9^'m9fW DX̊Mpgx?pGyV&><;|kuړ=a:jXqhG5>Y.r'E۲~Sϲm߀KrRY@W'$
oIAMC|[o5#dJ 5|d>eB]1Нe ^.bKIWk:G=BD?1@Gj0wR+V'V9|\ˈ68t TŔSN+%Bzo6a2Ś